Xcout IntelIDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Subscribe to see IDEAYA Biosciences, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
IDEAYA Biosciences, Inc. at a glance
IDEAYA Biosciences, Inc. is a biotech company headquartered in South San Francisco, United States. It is publicly listed (IDYA) with a market capitalisation of $3.4B. Xcout tracks 27 named people at IDEAYA Biosciences, Inc., including Yujiro S. Hata (Founder, Chairman and Chief Executive Officer). Xcout recorded 50 job postings from IDEAYA Biosciences, Inc. in the last 90 days, naming tools such as NetSuite.
IDEAYA Biosciences, Inc. leadership
- Yujiro S. HataFounder, Chairman and Chief Executive Officer
- Joshua BleharskiChief Financial Officer
- Paul A. BarsantiChief Technology Officer
- Darrin BeaupreChief Medical Officer
- Michael A. WhiteChief Scientific Officer
- Douglas SnyderChief Legal Officer
21 more named people on record for IDEAYA Biosciences, Inc., with roles, board committees and tenure — see the full roster →
IDEAYA Biosciences, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $94M | 3 named |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at IDEAYA Biosciences, Inc.
Xcout recorded 50 job postings from IDEAYA Biosciences, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
Tools named in IDEAYA Biosciences, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see IDEAYA Biosciences, Inc.'s hiring signals →
Investors
Tech stack
IDEAYA Biosciences, Inc. competitors
A few of IDEAYA Biosciences, Inc.'s closest competitors — see the full list of competitors and alternatives →
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical firm dedicated to the discovery and advancement of epigenetics-based therapies. Its primary focus is on treating cancer and central nervous system (CNS) disorders. The company's pipeline features two lead compounds in Phase II clinical trials: iadademstat (ORY-1001), a selective LSD1 inhibitor targeting oncology, and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for CNS applications, addressing neurological and psychiatric conditions. Furthermore, ORY-3001, another LSD1 inhibitor, is currently in preclinical development for a range of non-cancer-related illnesses. Founded in 2000, Oryzon Genomics S.A. is headquartered in Cornellà de Llobregat, Spain.
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
Tessellate Bio is a biotechnology company that develops precision oncology medicines by exploring synthetic lethal interactions beyond homologous recombination deficiency. The company integrates biomarker discovery and companion diagnostics into its research programs to create first-in-class treatments for hard-to-treat cancers.
Edison Oncology Holding Corp is a clinical-stage biopharmaceutical company that develops first-in-class, small-molecule, biomarker-driven therapies to target major cancer markets. The company identifies, acquires, and advances underdeveloped drug candidates to address critical unmet needs for cancer patients with specific genetic mutations.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Get IDEAYA Biosciences, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on IDEAYA Biosciences, Inc. in Xcout Intel
- 27 named people with titles, LinkedIn and board committees
- 1 funding round before the IPO with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access